Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | MMP2 | P08253 | 4/20 | 0.68 |
| ▸ | MMP9 | P14780 | 4/20 | 0.68 |
| ▸ | MMP8 | P22894 | 4/20 | 0.68 |
| ▸ | MMP13 | P45452 | 3/20 | 0.68 |
| ▸ | COMT | P21964 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679082 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL16050861 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL31412081 | 0.88 | KDM4E (0.79) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL3340887 | 0.87 | KDM4E (0.77) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL11599505 | 0.87 | KDM4E (0.77) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL17672255 | 0.87 | KDM4E (0.77) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL16148150 | 0.87 | KDM4E (0.76) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL27040203 | 0.86 | KDM4E (0.74) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL16147901 | 0.85 | MMP2 (0.75) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL31472953 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | NIMMUNE BIOPHARMA, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12502388-B2 | Lanthionine synthetase C-like 2-based therapeutics | NIMMUNE BIOPHARMA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3757099-B1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3757099-B1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220047554-A1 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS | UNIVERSITY OF VIRGINIA | 2022-02-17 | — | — | US | disclosed |
| US-11090289-B2 | Compositions and methods for blocking sodium channels | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-08-17 | — | — | US | disclosed |
| EP-3209655-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9556146-B2 | Lanthionine synthetase C-like 2-based therapeutics | BIOTHERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556146-B2 | Lanthionine synthetase C-like 2-based therapeutics | BIOTHERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502388-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | KDM4E 3829/4885ALDH1A1 4739/4885RAB9A 3489/4885 |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | KDM4E 3829/4885ALDH1A1 4739/4885RAB9A 3489/4885 |
| US-11090289-B2 | Compositions and methods for blocking sodium channels | SCN3A, SCN1B, SCN2B | KDM4E 4354/4885ALDH1A1 2497/4885RAB9A 2068/4885 |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | KDM4E 3829/4885ALDH1A1 4739/4885RAB9A 3489/4885 |
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | SCLY, CLCN2, CBS | KDM4E 2045/4885ALDH1A1 3796/4885RAB9A 3528/4885 |
| US-20220047554-A1 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS | SCN3A, SCN1B, SCN2B | KDM4E 4354/4885ALDH1A1 2497/4885RAB9A 2068/4885 |
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | KDM4E 3829/4885ALDH1A1 4739/4885RAB9A 3489/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | KDM4E 4606/4885ALDH1A1 3073/4885RAB9A 1733/4885 |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | KDM4E 3829/4885ALDH1A1 4739/4885RAB9A 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.